Salvage Treatment Experience in Advanced Synovial Sarcoma: a Multicenter Retrospective Analysis of the Anatolian Society of Medical Oncology

Basit Öğe Kaydı
dc.contributor.authorYetisyigit, Tarkan
dc.contributor.authorArpaci, Erkan
dc.contributor.authorSeber, Erdogan Selcuk
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorKos, Fatma Tugba
dc.contributor.authorSonmez, Ozlem Uysal
dc.contributor.authorAlici, Suleyman
dc.date.accessioned2024-04-24T17:28:17Z
dc.date.available2024-04-24T17:28:17Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: We aimed to evaluate prognostic factors and response rates to various treatment approaches to patients with synovial sarcoma in an advanced setting. Materials and Methods: We retrospectively reviewed the medical records of 55 patients (18 pts; 32.7% women) diagnosed with synovial sarcomas. Twenty had metastatic disease at the time of diagnosis while the remainder of the study group consisted of patients who developed metastatic or inoperable locally advanced disease during follow up. Results: The median follow up time was 15 months (range: 1-53). Regarding outcomes for the 55 patients, 3 and 5 year overall survival rates were 26% and 14%, respectively. In univariate analyses among demographic factors female gender was associated with a better outcome (p=0.030). Patients with early progressing disease (<2 years) had a worse prognosis when compared to patient group with late relapse, but this difference did not reach statistical significance (p=0.056). According to multivariate Cox regression analysis patients who had undergone metastasectomy had a significant survival advantage (p=0.044). The overall response rate to different salvage chemotherapy regimens given as second line treatment was around 42.9-53.9% for all regimes. There were no statistically significant differences between chemotherapy regimens given in either second or third line settings in terms of overall survival. Conclusions: We observed no major differences in terms of response rate and survival between different salvage chemotherapy regimens. Although metastatic disease still carries a poor prognosis, metastasectomy was found to be associated with improved survivalen_US
dc.identifier.doi10.7314/APJCP.2013.14.9.5185
dc.identifier.endpage5188en_US
dc.identifier.issn1513-7368
dc.identifier.issue9en_US
dc.identifier.pmid24175798
dc.identifier.scopus2-s2.0-84887582433
dc.identifier.scopusqualityQ3
dc.identifier.startpage5185en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2013.14.9.5185
dc.identifier.urihttps://hdl.handle.net/11468/20391
dc.identifier.volume14en_US
dc.identifier.wosWOS:000328273000042
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSynovial Sarcomaen_US
dc.subjectAdvanced Diseaseen_US
dc.subjectSalvage Chemotherapyen_US
dc.subjectPrognostic Factorsen_US
dc.subjectMetastasectomyen_US
dc.titleSalvage Treatment Experience in Advanced Synovial Sarcoma: a Multicenter Retrospective Analysis of the Anatolian Society of Medical Oncologyen_US
dc.titleSalvage Treatment Experience in Advanced Synovial Sarcoma: a Multicenter Retrospective Analysis of the Anatolian Society of Medical Oncology
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu